DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: TIKOSYN

Summary for Tradename: TIKOSYN

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 TIKOSYN

Pharmacology for Tradename: TIKOSYN

Drug ClassAntiarrhythmic

Clinical Trials for: TIKOSYN

Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Status: Active, not recruiting Condition: Drug-induced Surface ECG Changes

PVI Using Cryoablation Alone in Paroxysmal AtF Patients Converted From Persistent AF With Dofetilide
Status: Recruiting Condition: Persistent AF Converted to Paroxysmal AF or Sinus Rhythm

High Intensity Focused Ultrasound (HIFU) Ablation System Study
Status: Suspended Condition: Atrial Fibrillation

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
Status: Terminated Condition: Atrial Fibrillation; Heart Failure

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
Status: Recruiting Condition: Atrial Fibrillation

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Status: Completed Condition: Atrial Fibrillation

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
Status: Completed Condition: Paroxysmal Atrial Fibrillation

Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia
Status: Terminated Condition: Defibrillators, Implantable; Tachycardia, Ventricular

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
Status: Completed Condition: Atrial Fibrillation; Arrhythmia

Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF
Status: Recruiting Condition: Persistent Atrial Fibrillation

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931Oct 1, 1999RXNo6,124,363<disabled><disabled>
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931Oct 1, 1999RXYes6,124,363<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc